$3.58
+0.00 (+0.00%)
Open$3.52
Previous Close$3.58
Day High$3.60
Day Low$3.42
52W High$7.34
52W Low$2.71
Volume—
Avg Volume919.0K
Market Cap143.25M
P/E Ratio1,245.65
EPS$-0.39
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+965.1% upside
Current
$3.58
$3.58
Target
$38.13
$38.13
$23.34
$38.13 avg
$40.06
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 144.02M | 136.88M | 22.23M |
| Net Income | 146.2K | 125.1K | -3,026,461 |
| Profit Margin | 0.1% | 0.1% | -13.6% |
| EBITDA | 111.17M | 100.37M | -4,014,681 |
| Free Cash Flow | — | — | -2,971,274 |
| Rev Growth | +5.2% | +5.2% | +14.5% |
| Debt/Equity | 0.41 | 0.41 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |